Last week, Editas participated in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference, where we discussed the latest updates on EDIT-401 and our broader pipeline. Listen to the discussion here: https://t.co/lcmhcBq7DK.
#Guggenheim#invivo
At #AHA2026, Editas shared new preclinical data demonstrating the durability of EDIT-401. The findings presented support EDIT-401’s potential as a transformative therapy for people living with hyperlipidemia. Learn more: https://t.co/Wq5r4UcB8p. #invivo
Earlier today, Editas Medicine announced third quarter 2026 results and business updates. Read the full press release here: https://t.co/C6Dc58i4rA. #biotech#cardiovasculardisease#earnings
#NEWS: Editas Medicine Announces Third Quarter 2026 Results and Business Updates. Read the full press release here: https://t.co/C6Dc58i4rA. #cardiovasculardisease#invivo#earnings
Next week, we’ll be participating in a Fireside Chat at the Guggenheim 3rd Annual Healthcare Innovation Conference at 2:30 p.m. ET. Listen to the live webcast here: https://t.co/zUaHJG8W0V. #Guggenheim#healthcare#cardiovasculardisease
This Sunday, Editas Medicine will present new preclinical data on EDIT-401, our lead in vivo development candidate, at this year’s American Heart Association Scientific Sessions in Chicago. For more details, read here: https://t.co/MnmInL07u8. #AHA2026#invivo#geneediting
It was a pleasure to participate in this year’s ESGCT Annual Congress. We enjoyed connecting with researchers, innovators, and industry leaders from across the cell and gene therapy community. View our poster presentations here: https://t.co/7IgC51Cs7U.
#ESGCT2026#invivo
Next week, our President & CEO, Gilmore O’Neill, will join fellow industry leaders at @LongwoodLeaders Boston CEO for a panel on “Developing a Robust Pipeline”. We look forward to connecting with others and to an insightful discussion! #LongwoodHealthcareLeaders#BostonCEO
On Saturday, Team Editas participated in the @American_Heart Association 2026 Boston Heart Walk, connecting with colleagues and the greater Boston community around heart health. Thank you to AHA for bringing our community together, and to everyone who walked. #BostonHeartWalk
Attending ESGCT next week? Check out our posters featured during the Wednesday Poster Session from 1:30 p.m. – 3:30 p.m. CET. For more information on the presentations, read here: https://t.co/8N5hAMlooW.
#ESGCT2026#ESGCTHamburg2026#invivo#cardiovasculardisease
#NEWS: Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference. Read the press release for details: https://t.co/Elxj7YH2Z5.
#ESGCT2026#Guggenheim#invivo
Yesterday, we announced approval to initiate our Phase 1/2 Strive™ study of EDIT-401 in patients with Heterozygous Familial Hypercholesterolemia (HeFH) in Australia. Read the press release here: https://t.co/JlamKqx9b2.
#cardiovasculardisease#HeFH#geneediting#clinicaltrials
#NEWS: Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia. Read the press release for details: https://t.co/JlamKqx9b2.
#geneediting#HeFH#cardiovasculardisease#clinicaltrials
Last week, Editas participated in fireside chats at the Wells Fargo Healthcare Conference and Cantor Global Healthcare Conference, sharing updates on EDIT-401 and connecting with the wider healthcare and investment communities. Listen here: https://t.co/KR6VCJsBRf. #invivo
Tomorrow, we’ll be participating in a fireside chat at the 2026 Cantor Global Healthcare Conference at 3:55 p.m. ET. Tune in here: https://t.co/5JntlwygqA.
#geneediting#cardiovasculardisease#firesidechat
We’re thrilled to welcome Dan Ory, M.D., as Chief Medical Officer at Editas Medicine. Dr. Ory brings decades of experience in cardiovascular disease, genetic medicines, and clinical development as we advance EDIT-401 toward the clinic. Read more: https://t.co/vExpZW6qWQ #invivo
On Tuesday, we’ll be participating in a fireside chat at the Wells Fargo Healthcare Conference at 4:30 p.m. ET. Tune in here: https://t.co/xCgKNVQalo.
#invivo#cardiovasculardisease#firesidechat
Our President & CEO Gilmore O’Neill discusses the evolution of gene editing, the potential of in vivo approaches, and the opportunity to develop durable, potentially one-time therapies for patients with serious diseases: Read here: https://t.co/w1PFFuecq6. #biotech#leadership